Crenolanib

Drug Profile

Crenolanib

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals; University of Ulm
  • Class Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Acute myeloid leukaemia; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma; Non-small cell lung cancer
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Systemic mastocytosis
  • Research Soft tissue sarcoma
  • No development reported Cancer; Glioma

Most Recent Events

  • 01 Dec 2017 Crenolanib receives Fast Track designation for Acute myeloid leukaemia [PO] (Monotherapy, Combination therapy, Second-line therapy or greater) in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(In adolescents, In children, In infants, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top